Pfizer has a huge pipeline of new drugs that can hit the market in the next few years (sigvotatug vedotin for non-small cell lung cancer, atirmociclib for breast cancer, and PCV-25 for ...

Similarly, emerging oncology prospects atirmociclib and sigvotatug vedotin will need to differentiate themselves from established CDK inhibitors and ADC therapies in order to be able to justify ...

We recently published a list of 10 Most Profitable Value Stocks to Buy Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other profitable value ...

We recently published a list of 10 Most Profitable Value Stocks to Buy Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other profitable value stocks to ...

The company’s oncology pipeline includes several promising trials, such as atirmociclib for breast cancer and sigvotatug vedotin for lung cancer. Pfizer is expecting significant Phase 3 trial results ...

The company is actively running Phase 3 trials for atirmociclib in breast cancer, sigvotatug vedotin in lung cancer, and candida in head and neck and lung cancers. These trials aim to expand ...

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, and sells a range of medicines and vaccines across various therapeutic areas. These areas include ...

Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...